Small Cap
Diagnostics & Research
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Personalis
PSNL
$1.69B
| $1.69B | $15.82 | 0.69% |
|
|
FRNM
2
Freenome Inc
FRNM
$1.34B
| $1.34B | $12.48 | 2.95% |
|
3
Opko Health
OPK
$1.24B
| $1.24B | $1.66 | 0% |
|
4
Castle Biosciences
CSTL
$1.14B
| $1.14B | $37.16 | 3.51% |
|
5
Myriad Genetics
MYGN
$607M
| $607M | $6.35 | 4.8% |
|
6
Fulgent Genetics
FLGT
$567M
| $567M | $20.62 | 4.89% |
|
Small Cap Diagnostics & Research Stocks at a Glance
Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.
There are 6 small cap Diagnostics & Research stocks — companies in the Diagnostics & Research industry with a market cap between $250M and $2B — worth a combined $6.58B.
The largest by market cap are Personalis (PSNL) at $1.69B, Freenome Inc (FRNM) at $1.34B and Opko Health (OPK) at $1.24B.
Among institutional investors, Personalis (PSNL) drew the most net new fund positions in Q2 2026: 42 funds opened new positions, taking total fund holders up 18 (13%) quarter-over-quarter.
- Combined market cap: $6.58B across 6 stocks.
- Small Cap: market cap between $250M and $2B.
- Largest constituent: Personalis (PSNL), $1.69B market cap.
- Most net new fund positions in Q2 2026: Personalis (PSNL), +18 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.